# US 2015/0307837 A1 · Reprogramming of human whartons jelly cells to produce hair cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0307837 A1
- Document ID: US20150307837A1
- Status: Published application
- Kind: A1
- Application number: 14/698,157
- Filed: 2015-04-28
- Published: 2015-10-29
- Earliest claimed: 2014-04-28
- Assignees: University of Kansas
- Inventors: Adam J. Mellott; Michael Detamore; Hinrich Staecker
- Web page: https://patentgrep.com/patent/US20150307837A1

## CPC

- C12N 5/062: {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/51: in polymeric form, e.g. multimers, concatemers
- C12N 2506/025: from extra-embryonic cells, e.g. trophoblast, placenta
- C12N 2510/00: Genetically modified cells
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of transforming human cells into mechanosensory hair cells (MHCs), such as inner hear hair cells in the cochlea and vestibular organs, can include: causing human Wharton's jelly cells (hWJCs) to increase expression of or biological function of HATH1 so as to transform the hWJCs into MHCs. The method can include; administering a nucleic acid that encodes HATH1 to the hWJCs; causing inhibited expression of or biological function of HES1 and/or HES5 in the hWJCs; administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5 to the hWJCs; causing inhibited expression of or biological function of HES1 and/or HES5 in the WJCs by administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5; nucleic acids are administered includes a sequence of SEQ ID NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4.

## Claims

### Claim 1

A method of transforming human cells into mechanosensory hair cells (MHCs), the method comprising:
causing human Wharton's jelly cells (hWJCs) to increase expression of or biological function of HATH1 so as to transform the hWJCs into MHCs.

### Claim 2 (depends on 1)

The method of claim 1, comprising administering a nucleic acid that encodes HATH1 to the hWJCs.

### Claim 3 (depends on 1)

The method of claim 1, comprising:
causing inhibited expression of or biological function of HES1 and/or HES5 in the hWJCs.

### Claim 4 (depends on 3)

The method of claim 3, comprising administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5 to the hWJCs.

### Claim 5 (depends on 2)

The method of claim 2, comprising:
causing inhibited expression of or biological function of HES1 and/or HES5 in the WJCs by administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5.

### Claim 6 (depends on 5)

The method of claim 5, wherein the nucleic acids are administered to the WJCs by non-viral nucleic acid delivery.

### Claim 7 (depends on 6)

The method of claim 6, wherein the non-viral nucleic acid delivery is electroporation.

### Claim 8 (depends on 5)

The method of claim 5, wherein:
the nucleic acid that encodes HATH1 includes a sequence of SEQ ID NO: 2;
the nucleic acid that inhibits HES1 includes a sequence of SEQ ID NO: 3; and/or
the nucleic acid that inhibits HES5 includes a sequence of SEQ ID NO: 4.

### Claim 9 (depends on 1)

The method of claim 1, comprising:
seeding the transforming hWJCs or MHCs onto a substrate shaped as a cochlea.

### Claim 10 (depends on 9)

The method of claim 9, wherein the substrate is a decellularized cochlea.

### Claim 11 (depends on 10)

The method of claim 10, comprising perfusing the transforming hWJCs or MHCs onto the decellularized cochlea.

### Claim 12 (depends on 1)

The method of claim 1, comprising transforming the WJCs to the MHCs within 7 days.

### Claim 13

A method of providing mechanosensory hair cells (MHCs) to an inner ear of a subject, the method comprising:
causing human Wharton's jelly cells (hWJCs) to increase expression of or biological function of HATH1 so as to transform the hWJCs into MHCs; and
implanting the MHCs into the inner ear of the subject.

### Claim 14 (depends on 13)

The method of claim 13, wherein the implanted MHCs are sufficient to improve hearing and/or balance in the subject.

### Claim 15

A cell culture system comprising:
a decellularized cochlea; and
mechanosensory hair cells (MHCs) growing on the decellularized cochlea.

### Claim 16 (depends on 15)

The cell culture system of claim 15, wherein the MHCs are characterized as being derived from human Warton's jelly cells (WJCs) that have been transfected with a nucleic acid that encodes HATH1 and a nucleic acid that inhibits HES1 and a nucleic acid that inhibits HES5.

### Claim 17 (depends on 15)

The cell culture system of claim 15, comprising one or more test substances in the MHCs, the one or more test substances are not native to Warton's jelly cells (WJCs) or MHCs and are present in an amount to screen for biological activity thereof.

### Claim 18 (depends on 15)

A method of screening compounds for biological activity on mechanosensory hair cells (MHCs), the method comprising:
providing the system of claim 15;
administering a test substance to the MHCs; and
determining whether or not the test substance has biological activity on the MHCs.

### Claim 19 (depends on 18)

The method of claim 18, wherein when the test substance is determined to have a negative biological activity on the MHCs, the method comprising:
selecting the test substance for further testing of toxicity of the test substance on MHCs.

### Claim 20 (depends on 18)

The method of claim 18, wherein the test substance is determined to have a positive biological activity on the MHCs, the method comprising:
selecting the test substance for further testing of therapeutic benefit for treatment of hearing and/or balance loss.
